{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T16:29:23Z","timestamp":1795192163235,"version":"4.10.3"},"reference-count":147,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473387"],"award-info":[{"award-number":["82473387"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-66376-6","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T14:29:13Z","timestamp":1763389753000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Drug-tolerant persister cells in cancer: bridging the gaps between bench and bedside"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6820-8383","authenticated-orcid":false,"given":"Zhile","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1186-1792","authenticated-orcid":false,"given":"Mengyao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9560-0369","authenticated-orcid":false,"given":"Zheyu","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5087-8220","authenticated-orcid":false,"given":"Shensi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"66376_CR1","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.cell.2020.10.027","volume":"183","author":"S Shen","year":"2020","unstructured":"Shen, S., Vagner, S. & Robert, C. Persistent cancer cells: the deadly survivors. Cell 183, 860\u2013874 (2020).","journal-title":"Cell"},{"key":"66376_CR2","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s41568-024-00737-z","volume":"24","author":"M Russo","year":"2024","unstructured":"Russo, M. et al. Cancer drug-tolerant persister cells: from biological questions to clinical opportunities. Nat. Rev. Cancer 24, 694\u2013717 (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"66376_CR3","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41571-023-00815-5","volume":"20","author":"Y Pu","year":"2023","unstructured":"Pu, Y. et al. Drug-tolerant persister cells in cancer: the cutting edges and future directions. Nat. Rev. Clin. Oncol. 20, 799\u2013813 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"66376_CR4","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(00)74210-3","volume":"2","author":"JW Bigger","year":"1944","unstructured":"Bigger, J. W. Treatment of staphylococcal infections with penicillin - By intermittent sterilisation. Lancet 2, 497\u2013500 (1944).","journal-title":"Lancet"},{"key":"66376_CR5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","volume":"141","author":"SV Sharma","year":"2010","unstructured":"Sharma, S. V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69\u201380 (2010).","journal-title":"Cell"},{"key":"66376_CR6","doi-asserted-by":"publisher","first-page":"101471","DOI":"10.1016\/j.xcrm.2024.101471","volume":"5","author":"M Chen","year":"2024","unstructured":"Chen, M. et al. Targeting of vulnerabilities of drug-tolerant persisters identified through functional genetics delays tumor relapse. Cell Rep. Med. 5, 101471 (2024).","journal-title":"Cell Rep. Med."},{"key":"66376_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41811-8","volume":"14","author":"G Harmange","year":"2023","unstructured":"Harmange, G. et al. Disrupting cellular memory to overcome drug resistance. Nat. Commun. 14, 7130 (2023).","journal-title":"Nat. Commun."},{"key":"66376_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13360-6","volume":"10","author":"S Shen","year":"2019","unstructured":"Shen, S. et al. An epitranscriptomic mechanism underlies selective mRNA translation remodelling in melanoma persister cells. Nat. Commun. 10, 5713 (2019).","journal-title":"Nat. Commun."},{"key":"66376_CR9","doi-asserted-by":"publisher","first-page":"108421","DOI":"10.1016\/j.celrep.2020.108421","volume":"33","author":"S Shen","year":"2020","unstructured":"Shen, S. et al. Melanoma persister cells are tolerant to BRAF\/MEK inhibitors via ACOX1-mediated fatty acid oxidation. Cell Rep. 33, 108421 (2020).","journal-title":"Cell Rep."},{"key":"66376_CR10","doi-asserted-by":"publisher","first-page":"e2302878120","DOI":"10.1073\/pnas.2302878120","volume":"120","author":"Z Liu","year":"2023","unstructured":"Liu, Z. et al. CPT1A-mediated fatty acid oxidation confers cancer cell resistance to immune-mediated cytolytic killing. Proc. Natl. Acad. Sci. USA 120, e2302878120 (2023).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"66376_CR11","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1126\/science.aav4474","volume":"366","author":"M Russo","year":"2019","unstructured":"Russo, M. et al. Adaptive mutability of colorectal cancers in response to targeted therapies. Science 366, 1473\u20131480 (2019).","journal-title":"Science"},{"key":"66376_CR12","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1158\/2159-8290.CD-24-0046","volume":"14","author":"LD Grossmann","year":"2024","unstructured":"Grossmann, L. D. et al. Identification and characterization of chemotherapy-resistant high-risk neuroblastoma persister cells. Cancer Discov. 14, 2387\u20132406 (2024).","journal-title":"Cancer Discov."},{"key":"66376_CR13","doi-asserted-by":"publisher","first-page":"101663","DOI":"10.1016\/j.xcrm.2024.101663","volume":"5","author":"MJ Nokin","year":"2024","unstructured":"Nokin, M. J. et al. In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAF(V600E) lung adenocarcinoma. Cell Rep. Med. 5, 101663 (2024).","journal-title":"Cell Rep. Med."},{"key":"66376_CR14","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1016\/j.cell.2024.02.009","volume":"187","author":"C Swanton","year":"2024","unstructured":"Swanton, C. et al. Embracing cancer complexity: hallmarks of systemic disease. Cell 187, 1589\u20131616 (2024).","journal-title":"Cell"},{"key":"66376_CR15","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1158\/2159-8290.CD-20-1265","volume":"12","author":"CA Chang","year":"2022","unstructured":"Chang, C. A. et al. Ontogeny and vulnerabilities of drug-tolerant persisters in HER2+ breast cancer. Cancer Discov. 12, 1022\u20131045 (2022).","journal-title":"Cancer Discov."},{"key":"66376_CR16","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.cell.2018.06.025","volume":"174","author":"F Rambow","year":"2018","unstructured":"Rambow, F. et al. Toward minimal residual disease-directed therapy in melanoma. Cell 174, 843\u2013855.e819 (2018).","journal-title":"Cell"},{"key":"66376_CR17","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41586-023-06342-8","volume":"620","author":"Y Goyal","year":"2023","unstructured":"Goyal, Y. et al. Diverse clonal fates emerge upon drug treatment of homogeneous cancer cells. Nature 620, 651\u2013659 (2023).","journal-title":"Nature"},{"key":"66376_CR18","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41568-023-00642-x","volume":"24","author":"J Agudo","year":"2024","unstructured":"Agudo, J. et al. Targeting cancer cell dormancy. Nat. Rev. Cancer 24, 97\u2013104 (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"66376_CR19","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrclinonc.2017.44","volume":"14","author":"T Shibue","year":"2017","unstructured":"Shibue, T. & Weinberg, R. A. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat. Rev. Clin. Oncol. 14, 611\u2013629 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"66376_CR20","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/s41571-022-00668-4","volume":"19","author":"CA Schmitt","year":"2022","unstructured":"Schmitt, C. A., Wang, B. & Demaria, M. Senescence and cancer - role and therapeutic opportunities. Nat. Rev. Clin. Oncol. 19, 619\u2013636 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"66376_CR21","doi-asserted-by":"publisher","first-page":"6759","DOI":"10.1158\/0008-5472.CAN-17-1099","volume":"77","author":"F Falcetta","year":"2017","unstructured":"Falcetta, F. et al. Modeling cytostatic and cytotoxic responses to new treatment regimens for ovarian cancer. Cancer Res. 77, 6759\u20136769 (2017).","journal-title":"Cancer Res."},{"key":"66376_CR22","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1136\/bmj.2.4888.607","volume":"2","author":"G Hadfield","year":"1954","unstructured":"Hadfield, G. The dormant cancer cell. Br. Med. J. 2, 607\u2013610 (1954).","journal-title":"Br. Med. J."},{"key":"66376_CR23","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1093\/jnci\/85.17.1419","volume":"85","author":"K Pantel","year":"1993","unstructured":"Pantel, K. et al. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J. Natl. Cancer Inst. 85, 1419\u20131424 (1993).","journal-title":"J. Natl. Cancer Inst."},{"key":"66376_CR24","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41586-021-03796-6","volume":"596","author":"Y Oren","year":"2021","unstructured":"Oren, Y. et al. Cycling cancer persister cells arise from lineages with distinct programs. Nature 596, 576\u2013582 (2021).","journal-title":"Nature"},{"key":"66376_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28076-3","volume":"13","author":"L Borriello","year":"2022","unstructured":"Borriello, L. et al. Primary tumor associated macrophages activate programs of invasion and dormancy in disseminating tumor cells. Nat. Commun. 13, 626 (2022).","journal-title":"Nat. Commun."},{"key":"66376_CR26","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/s41588-022-01047-6","volume":"54","author":"J Marsolier","year":"2022","unstructured":"Marsolier, J. et al. H3K27me3 conditions chemotolerance in triple-negative breast cancer. Nat. Genet. 54, 459\u2013468 (2022).","journal-title":"Nat. Genet."},{"key":"66376_CR27","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nature22794","volume":"546","author":"SM Shaffer","year":"2017","unstructured":"Shaffer, S. M. et al. Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance. Nature 546, 431\u2013435 (2017).","journal-title":"Nature"},{"key":"66376_CR28","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ccell.2020.12.002","volume":"39","author":"E Dhimolea","year":"2021","unstructured":"Dhimolea, E. et al. An embryonic diapause-like adaptation with suppressed myc activity enables tumor treatment persistence. Cancer Cell 39, 240\u2013256.e211 (2021).","journal-title":"Cancer Cell"},{"key":"66376_CR29","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ccell.2023.12.011","volume":"42","author":"ET Goddard","year":"2024","unstructured":"Goddard, E. T. et al. Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies. Cancer Cell 42, 119\u2013134.e112 (2024).","journal-title":"Cancer Cell"},{"key":"66376_CR30","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.ccell.2023.01.007","volume":"41","author":"MB Nilsson","year":"2023","unstructured":"Nilsson, M. B. et al. CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance. Cancer Cell 41, 340\u2013355.e346 (2023).","journal-title":"Cancer Cell"},{"key":"66376_CR31","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1158\/1078-0432.CCR-15-2157","volume":"23","author":"PH Nguyen","year":"2017","unstructured":"Nguyen, P. H. et al. Characterization of biomarkers of tumorigenic and chemoresistant cancer stem cells in human gastric carcinoma. Clin. Cancer Res. 23, 1586\u20131597 (2017).","journal-title":"Clin. Cancer Res."},{"key":"66376_CR32","doi-asserted-by":"publisher","first-page":"5554","DOI":"10.1016\/j.cell.2023.11.004","volume":"186","author":"X Qin","year":"2023","unstructured":"Qin, X. et al. An oncogenic phenoscape of colonic stem cell polarization. Cell 186, 5554\u20135568.e5518 (2023).","journal-title":"Cell"},{"key":"66376_CR33","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.stem.2017.11.001","volume":"22","author":"S Yui","year":"2018","unstructured":"Yui, S. et al. YAP\/TAZ-dependent reprogramming of colonic epithelium links ECM remodeling to tissue regeneration. Cell Stem Cell 22, 35\u201349 e37 (2018).","journal-title":"Cell Stem Cell"},{"key":"66376_CR34","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.stem.2022.07.008","volume":"29","author":"EG Vasquez","year":"2022","unstructured":"Vasquez, E. G. et al. Dynamic and adaptive cancer stem cell population admixture in colorectal neoplasia. Cell Stem Cell 29, 1213\u20131228 e1218 (2022).","journal-title":"Cell Stem Cell"},{"key":"66376_CR35","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/s43018-022-00402-0","volume":"3","author":"A Alvarez-Varela","year":"2022","unstructured":"Alvarez-Varela, A. et al. Mex3a marks drug-tolerant persister colorectal cancer cells that mediate relapse after chemotherapy. Nat. Cancer 3, 1052\u20131070 (2022).","journal-title":"Nat. Cancer"},{"key":"66376_CR36","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.cell.2020.11.018","volume":"184","author":"SK Rehman","year":"2021","unstructured":"Rehman, S. K. et al. Colorectal cancer cells enter a diapause-like DTP state to survive chemotherapy. Cell 184, 226\u2013242 e221 (2021).","journal-title":"Cell"},{"key":"66376_CR37","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41588-024-02058-1","volume":"57","author":"S Mzoughi","year":"2025","unstructured":"Mzoughi, S. et al. Oncofetal reprogramming drives phenotypic plasticity in WNT-dependent colorectal cancer. Nat. Genet. 57, 402\u2013412 (2025).","journal-title":"Nat. Genet."},{"key":"66376_CR38","doi-asserted-by":"publisher","unstructured":"Li, M. et al. FXYD3 functionally demarcates an ancestral breast cancer stem cell subpopulation with features of drug-tolerant persisters. J. Clin. Invest. 133, https:\/\/doi.org\/10.1172\/JCI166666 (2023).","DOI":"10.1172\/JCI166666"},{"key":"66376_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54728-7","volume":"16","author":"S Punzi","year":"2025","unstructured":"Punzi, S. et al. Early tolerance and late persistence as alternative drug responses in cancer. Nat. Commun. 16, 1291 (2025).","journal-title":"Nat. Commun."},{"key":"66376_CR40","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.cell.2019.05.041","volume":"178","author":"CH Hsu","year":"2019","unstructured":"Hsu, C. H., Altschuler, S. J. & Wu, L. F. Patterns of early p21 dynamics determine proliferation-senescence cell fate after chemotherapy. Cell 178, 361\u2013373 e312 (2019).","journal-title":"Cell"},{"key":"66376_CR41","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ccell.2019.12.006","volume":"37","author":"KJ Kurppa","year":"2020","unstructured":"Kurppa, K. J. et al. Treatment-induced tumor dormancy through YAP-mediated transcriptional reprogramming of the apoptotic pathway. Cancer Cell 37, 104\u2013122 e112 (2020).","journal-title":"Cancer Cell"},{"key":"66376_CR42","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1158\/0008-5472.CAN-24-0529","volume":"85","author":"V Ramponi","year":"2025","unstructured":"Ramponi, V. et al. H4K20me3-mediated repression of inflammatory genes is a characteristic and targetable vulnerability of persister cancer cells. Cancer Res 85, 32\u201351 (2025).","journal-title":"Cancer Res"},{"key":"66376_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06478-z","volume":"15","author":"LJ Jenkins","year":"2024","unstructured":"Jenkins, L. J. et al. BCL-X(L) inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF(V600E) colorectal cancer. Cell Death Dis. 15, 183 (2024).","journal-title":"Cell Death Dis."},{"key":"66376_CR44","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1158\/1535-7163.MCT-10-0799","volume":"10","author":"ER Cantwell-Dorris","year":"2011","unstructured":"Cantwell-Dorris, E. R., O\u2019Leary, J. J. & Sheils, O. M. BRAFV600E: implications for carcinogenesis and molecular therapy. Mol. Cancer Ther. 10, 385\u2013394 (2011).","journal-title":"Mol. Cancer Ther."},{"key":"66376_CR45","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.canlet.2017.07.005","volume":"404","author":"A Borst","year":"2017","unstructured":"Borst, A. et al. BIK is involved in BRAF\/MEK inhibitor induced apoptosis in melanoma cell lines. Cancer Lett. 404, 70\u201378 (2017).","journal-title":"Cancer Lett."},{"key":"66376_CR46","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.bcp.2018.11.004","volume":"162","author":"FM Vallette","year":"2019","unstructured":"Vallette, F. M. et al. Dormant, quiescent, tolerant and persister cells: four synonyms for the same target in cancer. Biochem. Pharm. 162, 169\u2013176 (2019).","journal-title":"Biochem. Pharm."},{"key":"66376_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16212-w","volume":"11","author":"R Vander Velde","year":"2020","unstructured":"Vander Velde, R. et al. Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures. Nat. Commun. 11, 2393 (2020).","journal-title":"Nat. Commun."},{"key":"66376_CR48","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/s41586-024-07690-9","volume":"631","author":"GS Franca","year":"2024","unstructured":"Franca, G. S. et al. Cellular adaptation to cancer therapy along a resistance continuum. Nature 631, 876\u2013883 (2024).","journal-title":"Nature"},{"key":"66376_CR49","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1016\/j.cell.2022.07.025","volume":"185","author":"H Kalkavan","year":"2022","unstructured":"Kalkavan, H. et al. Sublethal cytochrome c release generates drug-tolerant persister cells. Cell 185, 3356\u20133374 e3322 (2022).","journal-title":"Cell"},{"key":"66376_CR50","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.1083\/jcb.201706134","volume":"216","author":"G Sun","year":"2017","unstructured":"Sun, G. et al. A molecular signature for anastasis, recovery from the brink of apoptotic cell death. J. Cell Biol. 216, 3355\u20133368 (2017).","journal-title":"J. Cell Biol."},{"key":"66376_CR51","doi-asserted-by":"publisher","first-page":"e2216531120","DOI":"10.1073\/pnas.2216531120","volume":"120","author":"M Nano","year":"2023","unstructured":"Nano, M., Mondo, J. A., Harwood, J., Balasanyan, V. & Montell, D. J. Cell survival following direct executioner-caspase activation. Proc. Natl. Acad. Sci. USA 120, e2216531120 (2023).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"66376_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07788-5","volume":"9","author":"S Chakrabarti","year":"2018","unstructured":"Chakrabarti, S. et al. Hidden heterogeneity and circadian-controlled cell fate inferred from single cell lineages. Nat. Commun. 9, 5372 (2018).","journal-title":"Nat. Commun."},{"key":"66376_CR53","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.cels.2017.07.005","volume":"5","author":"T Ryl","year":"2017","unstructured":"Ryl, T. et al. Cell-cycle position of single MYC-driven cancer cells dictates their susceptibility to a chemotherapeutic drug. Cell Syst. 5, 237\u2013250 e238 (2017).","journal-title":"Cell Syst."},{"key":"66376_CR54","doi-asserted-by":"publisher","first-page":"e3000178","DOI":"10.1371\/journal.pbio.3000178","volume":"17","author":"M Min","year":"2019","unstructured":"Min, M. & Spencer, S. L. Spontaneously slow-cycling subpopulations of human cells originate from activation of stress-response pathways. PLoS Biol. 17, e3000178 (2019).","journal-title":"PLoS Biol."},{"key":"66376_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40823-8","volume":"14","author":"M Szaruga","year":"2023","unstructured":"Szaruga, M. et al. Activation of the integrated stress response by inhibitors of its kinases. Nat. Commun. 14, 5535 (2023).","journal-title":"Nat. Commun."},{"key":"66376_CR56","doi-asserted-by":"publisher","unstructured":"Ill, C. R. et al. BRAF(V600) and ErbB inhibitors directly activate GCN2 in an off-target manner to limit cancer cell proliferation. Preprint at bioRxiv. https:\/\/doi.org\/10.1101\/2024.12.19.629301 (2024).","DOI":"10.1101\/2024.12.19.629301"},{"key":"66376_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114606","volume":"43","author":"AP Drainas","year":"2024","unstructured":"Drainas, A. P. et al. GCN2 is a determinant of the response to WEE1 kinase inhibition in small-cell lung cancer. Cell Rep. 43, 114606 (2024).","journal-title":"Cell Rep."},{"key":"66376_CR58","doi-asserted-by":"publisher","unstructured":"Saavedra-Garcia, P. et al. Systems level profiling of chemotherapy-induced stress resolution in cancer cells reveals druggable trade-offs. Proc. Natl. Acad. Sci. USA 118, https:\/\/doi.org\/10.1073\/pnas.2018229118 (2021).","DOI":"10.1073\/pnas.2018229118"},{"key":"66376_CR59","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41586-024-08506-6","volume":"639","author":"J Fanous","year":"2025","unstructured":"Fanous, J. et al. Limited impact of Salmonella stress and persisters on antibiotic clearance. Nature 639, 181\u2013189 (2025).","journal-title":"Nature"},{"key":"66376_CR60","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1038\/s42255-024-01166-w","volume":"6","author":"M Nam","year":"2024","unstructured":"Nam, M. et al. Glucose limitation protects cancer cells from apoptosis induced by pyrimidine restriction and replication inhibition. Nat. Metab. 6, 2338\u20132353 (2024).","journal-title":"Nat. Metab."},{"key":"66376_CR61","doi-asserted-by":"publisher","unstructured":"Meng, F. et al. RIOK1 phase separation restricts PTEN translation via stress granules activating tumor growth in hepatocellular carcinoma. Nat. Cancer. https:\/\/doi.org\/10.1038\/s43018-025-00984-5 (2025).","DOI":"10.1038\/s43018-025-00984-5"},{"key":"66376_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57911-6","volume":"16","author":"M Nadal-Ribelles","year":"2025","unstructured":"Nadal-Ribelles, M. et al. Transcriptional heterogeneity shapes stress-adaptive responses in yeast. Nat. Commun. 16, 2631 (2025).","journal-title":"Nat. Commun."},{"key":"66376_CR63","doi-asserted-by":"publisher","first-page":"eabk2022","DOI":"10.1126\/sciadv.abk2022","volume":"8","author":"P Klein","year":"2022","unstructured":"Klein, P. et al. Temporal control of the integrated stress response by a stochastic molecular switch. Sci. Adv. 8, eabk2022 (2022).","journal-title":"Sci. Adv."},{"key":"66376_CR64","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1093\/genetics\/28.6.491","volume":"28","author":"SE Luria","year":"1943","unstructured":"Luria, S. E. & Delbruck, M. Mutations of bacteria from virus sensitivity to virus resistance. Genetics 28, 491\u2013511 (1943).","journal-title":"Genetics"},{"key":"66376_CR65","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/s41588-020-0645-y","volume":"52","author":"Z Meir","year":"2020","unstructured":"Meir, Z., Mukamel, Z., Chomsky, E., Lifshitz, A. & Tanay, A. Single-cell analysis of clonal maintenance of transcriptional and epigenetic states in cancer cells. Nat. Genet. 52, 709\u2013718 (2020).","journal-title":"Nat. Genet."},{"key":"66376_CR66","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.cell.2020.07.003","volume":"182","author":"SM Shaffer","year":"2020","unstructured":"Shaffer, S. M. et al. Memory sequencing reveals heritable single-cell gene expression programs associated with distinct cellular behaviors. Cell 182, 947\u2013959 e917 (2020).","journal-title":"Cell"},{"key":"66376_CR67","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41568-023-00656-5","volume":"24","author":"E Cambria","year":"2024","unstructured":"Cambria, E. et al. Linking cell mechanical memory and cancer metastasis. Nat. Rev. Cancer 24, 216\u2013228 (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"66376_CR68","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.biomaterials.2017.09.012","volume":"146","author":"S Nasrollahi","year":"2017","unstructured":"Nasrollahi, S. et al. Past matrix stiffness primes epithelial cells and regulates their future collective migration through a mechanical memory. Biomaterials 146, 146\u2013155 (2017).","journal-title":"Biomaterials"},{"key":"66376_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109293","volume":"35","author":"AW Watson","year":"2021","unstructured":"Watson, A. W. et al. Breast tumor stiffness instructs bone metastasis via maintenance of mechanical conditioning. Cell Rep. 35, 109293 (2021).","journal-title":"Cell Rep."},{"key":"66376_CR70","doi-asserted-by":"publisher","DOI":"10.15252\/msb.202010141","volume":"17","author":"K Radic Shechter","year":"2021","unstructured":"Radic Shechter, K. et al. Metabolic memory underlying minimal residual disease in breast cancer. Mol. Syst. Biol. 17, e10141 (2021).","journal-title":"Mol. Syst. Biol."},{"key":"66376_CR71","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.cell.2009.12.034","volume":"140","author":"DR Burrill","year":"2010","unstructured":"Burrill, D. R. & Silver, P. A. Making cellular memories. Cell 140, 13\u201318 (2010).","journal-title":"Cell"},{"key":"66376_CR72","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/418591a","volume":"418","author":"HG Dohlman","year":"2002","unstructured":"Dohlman, H. G. Diminishing returns. Nature 418, 591 (2002).","journal-title":"Nature"},{"key":"66376_CR73","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.cell.2011.01.030","volume":"144","author":"G Balazsi","year":"2011","unstructured":"Balazsi, G., van Oudenaarden, A. & Collins, J. J. Cellular decision making and biological noise: from microbes to mammals. Cell 144, 910\u2013925 (2011).","journal-title":"Cell"},{"key":"66376_CR74","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.cell.2013.10.046","volume":"155","author":"F Caudron","year":"2013","unstructured":"Caudron, F. & Barral, Y. A super-assembly of Whi3 encodes memory of deceptive encounters by single cells during yeast courtship. Cell 155, 1244\u20131257 (2013).","journal-title":"Cell"},{"key":"66376_CR75","doi-asserted-by":"publisher","first-page":"e1009348","DOI":"10.1371\/journal.pcbi.1009348","volume":"17","author":"T Cassidy","year":"2021","unstructured":"Cassidy, T., Nichol, D., Robertson-Tessi, M., Craig, M. & Anderson, A. R. A. The role of memory in non-genetic inheritance and its impact on cancer treatment resistance. PLoS Comput. Biol. 17, e1009348 (2021).","journal-title":"PLoS Comput. Biol."},{"key":"66376_CR76","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/s43018-021-00261-1","volume":"2","author":"A Jacob Berger","year":"2021","unstructured":"Jacob Berger, A. et al. IRS1 phosphorylation underlies the non-stochastic probability of cancer cells to persist during EGFR inhibition therapy. Nat. Cancer 2, 1055\u20131070 (2021).","journal-title":"Nat. Cancer"},{"key":"66376_CR77","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/s41586-023-06303-1","volume":"620","author":"H Isozaki","year":"2023","unstructured":"Isozaki, H. et al. Therapy-induced APOBEC3A drives evolution of persistent cancer cells. Nature 620, 393\u2013401 (2023).","journal-title":"Nature"},{"key":"66376_CR78","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1158\/2159-8290.CD-22-0111","volume":"12","author":"A Noronha","year":"2022","unstructured":"Noronha, A. et al. AXL and error-prone DNA replication confer drug resistance and offer strategies to treat EGFR-mutant lung cancer. Cancer Discov. 12, 2666\u20132683 (2022).","journal-title":"Cancer Discov."},{"key":"66376_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10690","volume":"7","author":"M Ramirez","year":"2016","unstructured":"Ramirez, M. et al. Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells. Nat. Commun. 7, 10690 (2016).","journal-title":"Nat. Commun."},{"key":"66376_CR80","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.adw3231","volume":"18","author":"V Nangia","year":"2025","unstructured":"Nangia, V. et al. MAPK and mTORC1 signaling converge to drive cyclin D1 protein production to enable cell cycle reentry in melanoma persister cells. Sci. Signal 18, eadw3231 (2025).","journal-title":"Sci. Signal"},{"key":"66376_CR81","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.1016\/j.molcel.2021.10.017","volume":"81","author":"CP Zampetidis","year":"2021","unstructured":"Zampetidis, C. P. et al. A recurrent chromosomal inversion suffices for driving escape from oncogene-induced senescence via subTAD reorganization. Mol. Cell 81, 4907\u20134923.e4908 (2021).","journal-title":"Mol. Cell"},{"key":"66376_CR82","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41586-020-03064-z","volume":"591","author":"O Shoshani","year":"2021","unstructured":"Shoshani, O. et al. Chromothripsis drives the evolution of gene amplification in cancer. Nature 591, 137\u2013141 (2021).","journal-title":"Nature"},{"key":"66376_CR83","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1158\/2159-8290.CD-22-0787","volume":"13","author":"P Dharanipragada","year":"2023","unstructured":"Dharanipragada, P. et al. Blocking genomic instability prevents acquired resistance to MAPK inhibitor therapy in melanoma. Cancer Discov. 13, 880\u2013909 (2023).","journal-title":"Cancer Discov."},{"key":"66376_CR84","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1158\/2159-8290.CD-23-0656","volume":"14","author":"S Pal Choudhuri","year":"2024","unstructured":"Pal Choudhuri, S. et al. Acquired cross-resistance in small cell lung cancer due to extrachromosomal DNA amplification of MYC paralogs. Cancer Discov. 14, 804\u2013827 (2024).","journal-title":"Cancer Discov."},{"key":"66376_CR85","doi-asserted-by":"publisher","first-page":"6055","DOI":"10.1016\/j.cell.2024.08.001","volume":"187","author":"JL Engel","year":"2024","unstructured":"Engel, J. L. et al. The Fanconi anemia pathway induces chromothripsis and ecDNA-driven cancer drug resistance. Cell 187, 6055\u20136070.e6022 (2024).","journal-title":"Cell"},{"key":"66376_CR86","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1158\/2159-8290.CD-20-0936","volume":"12","author":"K Song","year":"2022","unstructured":"Song, K. et al. Plasticity of extrachromosomal and intrachromosomal BRAF amplifications in overcoming targeted therapy dosage challenges. Cancer Discov. 12, 1046\u20131069 (2022).","journal-title":"Cancer Discov."},{"key":"66376_CR87","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1091\/mbc.e11-11-0926","volume":"23","author":"HL Tang","year":"2012","unstructured":"Tang, H. L. et al. Cell survival, DNA damage, and oncogenic transformation after a transient and reversible apoptotic response. Mol. Biol. Cell 23, 2240\u20132252 (2012).","journal-title":"Mol. Biol. Cell"},{"key":"66376_CR88","doi-asserted-by":"publisher","unstructured":"Vitiello, P. P. et al. Cisplatin and temozolomide combinatorial treatment triggers hypermutability and immune surveillance in experimental cancer models. Cancer Cell. https:\/\/doi.org\/10.1016\/j.ccell.2025.05.014 (2025).","DOI":"10.1016\/j.ccell.2025.05.014"},{"key":"66376_CR89","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abi7711","volume":"8","author":"X Sun","year":"2022","unstructured":"Sun, X. et al. Modulating environmental signals to reveal mechanisms and vulnerabilities of cancer persisters. Sci. Adv. 8, eabi7711 (2022).","journal-title":"Sci. Adv."},{"key":"66376_CR90","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41590-022-01290-3","volume":"23","author":"M Musella","year":"2022","unstructured":"Musella, M. et al. Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B. Nat. Immunol. 23, 1379\u20131392 (2022).","journal-title":"Nat. Immunol."},{"key":"66376_CR91","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14987-6","volume":"11","author":"E Brenner","year":"2020","unstructured":"Brenner, E. et al. Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours. Nat. Commun. 11, 1335 (2020).","journal-title":"Nat. Commun."},{"key":"66376_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.115388","volume":"44","author":"P Pereira","year":"2025","unstructured":"Pereira, P. et al. Inflammatory cytokines mediate the induction of and awakening from metastatic dormancy. Cell Rep. 44, 115388 (2025).","journal-title":"Cell Rep."},{"key":"66376_CR93","doi-asserted-by":"publisher","unstructured":"He, D. et al. Chemotherapy awakens dormant cancer cells in lung by inducing neutrophil extracellular traps. Cancer Cell. https:\/\/doi.org\/10.1016\/j.ccell.2025.06.007 (2025).","DOI":"10.1016\/j.ccell.2025.06.007"},{"key":"66376_CR94","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1038\/s43018-022-00466-y","volume":"3","author":"A Shahbandi","year":"2022","unstructured":"Shahbandi, A. et al. Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80. Nat. Cancer 3, 1513\u20131533 (2022).","journal-title":"Nat. Cancer"},{"key":"66376_CR95","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41586-024-08439-0","volume":"638","author":"H Ikeda","year":"2025","unstructured":"Ikeda, H. et al. Immune evasion through mitochondrial transfer in the tumour microenvironment. Nature 638, 225\u2013236 (2025).","journal-title":"Nature"},{"key":"66376_CR96","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41586-022-05426-1","volume":"612","author":"M Schmitt","year":"2022","unstructured":"Schmitt, M. et al. Colon tumour cell death causes mTOR dependence by paracrine P2X4 stimulation. Nature 612, 347\u2013353 (2022).","journal-title":"Nature"},{"key":"66376_CR97","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.cell.2015.01.043","volume":"160","author":"N Oshimori","year":"2015","unstructured":"Oshimori, N., Oristian, D. & Fuchs, E. TGF-beta promotes heterogeneity and drug resistance in squamous cell carcinoma. Cell 160, 963\u2013976 (2015).","journal-title":"Cell"},{"key":"66376_CR98","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nature11183","volume":"487","author":"R Straussman","year":"2012","unstructured":"Straussman, R. et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487, 500\u2013504 (2012).","journal-title":"Nature"},{"key":"66376_CR99","doi-asserted-by":"publisher","unstructured":"Cohen Shvefel, S. et al. Temporal genomic analysis of homogeneous tumor models reveals key regulators of immune evasion in melanoma. Cancer Discov. OF1\u2013OF25 https:\/\/doi.org\/10.1158\/2159-8290.CD-23-1422 (2025).","DOI":"10.1158\/2159-8290.CD-23-1422"},{"key":"66376_CR100","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","volume":"27","author":"J Yu","year":"2021","unstructured":"Yu, J. et al. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nat. Med. 27, 152\u2013164 (2021).","journal-title":"Nat. Med."},{"key":"66376_CR101","doi-asserted-by":"publisher","unstructured":"Rademaker, G. et al. PCSK9 drives sterol-dependent metastatic organ choice in pancreatic cancer. Nature. https:\/\/doi.org\/10.1038\/s41586-025-09017-8 (2025).","DOI":"10.1038\/s41586-025-09017-8"},{"key":"66376_CR102","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/j.ccell.2025.04.001","volume":"43","author":"S Gurung","year":"2025","unstructured":"Gurung, S. et al. Stromal lipid species dictate melanoma metastasis and tropism. Cancer Cell 43, 1108\u20131124 e1111 (2025).","journal-title":"Cancer Cell"},{"key":"66376_CR103","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nature24297","volume":"551","author":"MJ Hangauer","year":"2017","unstructured":"Hangauer, M. J. et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature 551, 247\u2013250 (2017).","journal-title":"Nature"},{"key":"66376_CR104","doi-asserted-by":"publisher","unstructured":"Remsik, J. et al. Interferon-gamma orchestrates leptomeningeal anti-tumour response. Nature. https:\/\/doi.org\/10.1038\/s41586-025-09012-z (2025).","DOI":"10.1038\/s41586-025-09012-z"},{"key":"66376_CR105","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.566297","volume":"10","author":"O Humbert","year":"2020","unstructured":"Humbert, O. & Chardin, D. Dissociated response in metastatic cancer: an atypical pattern brought into the spotlight with immunotherapy. Front. Oncol. 10, 566297 (2020).","journal-title":"Front. Oncol."},{"key":"66376_CR106","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41586-022-05374-w","volume":"611","author":"M Balood","year":"2022","unstructured":"Balood, M. et al. Nociceptor neurons affect cancer immunosurveillance. Nature 611, 405\u2013412 (2022).","journal-title":"Nature"},{"key":"66376_CR107","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41568-019-0222-9","volume":"20","author":"M Fane","year":"2020","unstructured":"Fane, M. & Weeraratna, A. T. How the ageing microenvironment influences tumour progression. Nat. Rev. Cancer 20, 89\u2013106 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"66376_CR108","doi-asserted-by":"publisher","first-page":"5347","DOI":"10.1158\/1078-0432.CCR-18-1116","volume":"24","author":"CH Kugel","year":"2018","unstructured":"Kugel, C. H. et al. Age correlates with response to anti-PD1, reflecting age-related differences in intratumoral effector and regulatory T-cell populations. Clin. Cancer Res. 24, 5347\u20135356 (2018).","journal-title":"Clin. Cancer Res."},{"key":"66376_CR109","doi-asserted-by":"publisher","first-page":"e381","DOI":"10.1634\/theoncologist.2019-0377","volume":"25","author":"V Jain","year":"2020","unstructured":"Jain, V. et al. Association of age with efficacy of immunotherapy in metastatic melanoma. Oncologist 25, e381\u2013e385 (2020).","journal-title":"Oncologist"},{"key":"66376_CR110","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22560-y","volume":"12","author":"K Chatsirisupachai","year":"2021","unstructured":"Chatsirisupachai, K., Lesluyes, T., Paraoan, L., Van Loo, P. & de Magalhaes, J. P. An integrative analysis of the age-associated multi-omic landscape across cancers. Nat. Commun. 12, 2345 (2021).","journal-title":"Nat. Commun."},{"key":"66376_CR111","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109599","volume":"36","author":"R Erbe","year":"2021","unstructured":"Erbe, R. et al. Evaluating the impact of age on immune checkpoint therapy biomarkers. Cell Rep. 36, 109599 (2021).","journal-title":"Cell Rep."},{"key":"66376_CR112","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55164-3","volume":"15","author":"R Duan","year":"2024","unstructured":"Duan, R. et al. Aging-induced immune microenvironment remodeling fosters melanoma in male mice via gammadelta17-Neutrophil-CD8 axis. Nat. Commun. 15, 10860 (2024).","journal-title":"Nat. Commun."},{"key":"66376_CR113","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/s41586-022-04774-2","volume":"606","author":"ME Fane","year":"2022","unstructured":"Fane, M. E. et al. Stromal changes in the aged lung induce an emergence from melanoma dormancy. Nature 606, 396\u2013405 (2022).","journal-title":"Nature"},{"key":"66376_CR114","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/s41568-021-00348-y","volume":"21","author":"S Haupt","year":"2021","unstructured":"Haupt, S., Caramia, F., Klein, S. L., Rubin, J. B. & Haupt, Y. Sex disparities matter in cancer development and therapy. Nat. Rev. Cancer 21, 393\u2013407 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"66376_CR115","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cell.2021.01.002","volume":"184","author":"K Litchfield","year":"2021","unstructured":"Litchfield, K. et al. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell 184, 596\u2013614.e514 (2021).","journal-title":"Cell"},{"key":"66376_CR116","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/s41586-022-04522-6","volume":"606","author":"X Guan","year":"2022","unstructured":"Guan, X. et al. Androgen receptor activity in T cells limits checkpoint blockade efficacy. Nature 606, 791\u2013796 (2022).","journal-title":"Nature"},{"key":"66376_CR117","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abq2630","volume":"7","author":"H Kwon","year":"2022","unstructured":"Kwon, H. et al. Androgen conspires with the CD8(+) T cell exhaustion program and contributes to sex bias in cancer. Sci. Immunol. 7, eabq2630 (2022).","journal-title":"Sci. Immunol."},{"key":"66376_CR118","doi-asserted-by":"publisher","unstructured":"Chakraborty, B. et al. Inhibition of estrogen signaling in myeloid cells increases tumor immunity in melanoma. J. Clin. Invest. 131, https:\/\/doi.org\/10.1172\/JCI151347 (2021).","DOI":"10.1172\/JCI151347"},{"key":"66376_CR119","doi-asserted-by":"publisher","first-page":"e2418096121","DOI":"10.1073\/pnas.2418096121","volume":"121","author":"I Naciri","year":"2024","unstructured":"Naciri, I. et al. Loss of XIST lncRNA unlocks stemness and cellular plasticity in ovarian cancer. Proc. Natl. Acad. Sci. USA 121, e2418096121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"66376_CR120","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1001\/jamaoncol.2016.0732","volume":"2","author":"CH Kroenke","year":"2016","unstructured":"Kroenke, C. H. et al. Analysis of body mass index and mortality in patients with colorectal cancer using causal diagrams. JAMA Oncol. 2, 1137\u20131145 (2016).","journal-title":"JAMA Oncol."},{"key":"66376_CR121","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/S1470-2045(18)30078-0","volume":"19","author":"JL McQuade","year":"2018","unstructured":"McQuade, J. L. et al. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 19, 310\u2013322 (2018).","journal-title":"Lancet Oncol."},{"key":"66376_CR122","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-018-1087-7","volume":"21","author":"BL Ecker","year":"2019","unstructured":"Ecker, B. L. et al. Impact of obesity on breast cancer recurrence and minimal residual disease. Breast Cancer Res. 21, 41 (2019).","journal-title":"Breast Cancer Res."},{"key":"66376_CR123","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2204758119","volume":"119","author":"R Roy","year":"2022","unstructured":"Roy, R. et al. Escape from breast tumor dormancy: the convergence of obesity and menopause. Proc. Natl. Acad. Sci. USA 119, e2204758119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"66376_CR124","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/s42003-024-06190-w","volume":"7","author":"M Pfeifer","year":"2024","unstructured":"Pfeifer, M. et al. Genome-wide CRISPR screens identify the YAP\/TEAD axis as a driver of persister cells in EGFR mutant lung cancer. Commun. Biol. 7, 497 (2024).","journal-title":"Commun. Biol."},{"key":"66376_CR125","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/j.ccell.2021.09.003","volume":"39","author":"H Hu","year":"2021","unstructured":"Hu, H. et al. Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms. Cancer Cell 39, 1531\u20131547 e1510 (2021).","journal-title":"Cancer Cell"},{"key":"66376_CR126","doi-asserted-by":"publisher","unstructured":"Wang, M. X. et al. Antigenic cancer persister cells survive direct T cell attack. Preprint at bioRxiv. https:\/\/doi.org\/10.1101\/2025.03.14.643359 (2025).","DOI":"10.1101\/2025.03.14.643359"},{"key":"66376_CR127","doi-asserted-by":"publisher","unstructured":"Baldacci, S. et al. Eradicating drug tolerant persister cells in EGFR-mutated non-small cell lung cancer by targeting TROP2 with CAR-T cellular therapy. Cancer Discov. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-1515 (2025).","DOI":"10.1158\/2159-8290.CD-24-1515"},{"key":"66376_CR128","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41586-019-1884-x","volume":"577","author":"JY Xue","year":"2020","unstructured":"Xue, J. Y. et al. Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition. Nature 577, 421\u2013425 (2020).","journal-title":"Nature"},{"key":"66376_CR129","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1158\/0008-5472.CAN-23-0144","volume":"83","author":"JL Cotton","year":"2023","unstructured":"Cotton, J. L. et al. Expressed barcoding enables high-resolution tracking of the evolution of drug tolerance. Cancer Res. 83, 3611\u20133623 (2023).","journal-title":"Cancer Res."},{"key":"66376_CR130","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41586-021-04206-7","volume":"601","author":"KA Fennell","year":"2022","unstructured":"Fennell, K. A. et al. Non-genetic determinants of malignant clonal fitness at single-cell resolution. Nature 601, 125\u2013131 (2022).","journal-title":"Nature"},{"key":"66376_CR131","doi-asserted-by":"publisher","first-page":"3945","DOI":"10.1016\/j.cell.2023.07.013","volume":"186","author":"Y Geffen","year":"2023","unstructured":"Geffen, Y. et al. Pan-cancer analysis of post-translational modifications reveals shared patterns of protein regulation. Cell 186, 3945\u20133967 e3926 (2023).","journal-title":"Cell"},{"key":"66376_CR132","doi-asserted-by":"publisher","unstructured":"Baudre, L. et al. Characterization of drug-tolerant persister cells in triple-negative breast cancer identifies a shared persistence program across treatments and patients. Cancer Res. https:\/\/doi.org\/10.1158\/0008-5472.CAN-25-0995 (2025).","DOI":"10.1158\/0008-5472.CAN-25-0995"},{"key":"66376_CR133","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41586-024-08150-0","volume":"637","author":"A Moorman","year":"2025","unstructured":"Moorman, A. et al. Progressive plasticity during colorectal cancer metastasis. Nature 637, 947\u2013954 (2025).","journal-title":"Nature"},{"key":"66376_CR134","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41592-021-01336-8","volume":"19","author":"MD Luecken","year":"2022","unstructured":"Luecken, M. D. et al. Benchmarking atlas-level data integration in single-cell genomics. Nat. Methods 19, 41\u201350 (2022).","journal-title":"Nat. Methods"},{"key":"66376_CR135","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36439-7","volume":"14","author":"G Malagoli Tagliazucchi","year":"2023","unstructured":"Malagoli Tagliazucchi, G., Wiecek, A. J., Withnell, E. & Secrier, M. Genomic and microenvironmental heterogeneity shaping epithelial-to-mesenchymal trajectories in cancer. Nat. Commun. 14, 789 (2023).","journal-title":"Nat. Commun."},{"key":"66376_CR136","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-024-03428-y","volume":"25","author":"E Withnell","year":"2024","unstructured":"Withnell, E. & Secrier, M. SpottedPy quantifies relationships between spatial transcriptomic hotspots and uncovers environmental cues of epithelial-mesenchymal plasticity in breast cancer. Genome Biol. 25, 289 (2024).","journal-title":"Genome Biol."},{"key":"66376_CR137","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1126\/science.abg5784","volume":"373","author":"TD Martin","year":"2021","unstructured":"Martin, T. D. et al. The adaptive immune system is a major driver of selection for tumor suppressor gene inactivation. Science 373, 1327\u20131335 (2021).","journal-title":"Science"},{"key":"66376_CR138","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.cels.2021.04.005","volume":"12","author":"D DeTomaso","year":"2021","unstructured":"DeTomaso, D. & Yosef, N. Hotspot identifies informative gene modules across modalities of single-cell genomics. Cell Syst. 12, 446\u2013456.e449 (2021).","journal-title":"Cell Syst."},{"key":"66376_CR139","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/s41586-024-08378-w","volume":"638","author":"J Xiang","year":"2025","unstructured":"Xiang, J. et al. A vision-language foundation model for precision oncology. Nature 638, 769\u2013778 (2025).","journal-title":"Nature"},{"key":"66376_CR140","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51071-9","volume":"15","author":"P Shrestha","year":"2024","unstructured":"Shrestha, P., Kandel, J., Tayara, H. & Chong, K. T. Post-translational modification prediction via prompt-based fine-tuning of a GPT-2 model. Nat. Commun. 15, 6699 (2024).","journal-title":"Nat. Commun."},{"key":"66376_CR141","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.tips.2023.06.010","volume":"44","author":"FW Pun","year":"2023","unstructured":"Pun, F. W., Ozerov, I. V. & Zhavoronkov, A. AI-powered therapeutic target discovery. Trends Pharm. Sci. 44, 561\u2013572 (2023).","journal-title":"Trends Pharm. Sci."},{"key":"66376_CR142","doi-asserted-by":"publisher","unstructured":"Gonzalez, G. et al. Combinatorial prediction of therapeutic perturbations using causally inspired neural networks. Nat. Biomed. Eng. https:\/\/doi.org\/10.1038\/s41551-025-01481-x (2025).","DOI":"10.1038\/s41551-025-01481-x"},{"key":"66376_CR143","doi-asserted-by":"publisher","unstructured":"Swanson, K., Wu, W., Bulaong, N. L., Pak, J. E. & Zou, J. The virtual lab of AI agents designs new SARS-CoV-2 nanobodies. Nature. https:\/\/doi.org\/10.1038\/s41586-025-09442-9 (2025).","DOI":"10.1038\/s41586-025-09442-9"},{"key":"66376_CR144","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1038\/s43018-024-00819-9","volume":"5","author":"X Sun","year":"2024","unstructured":"Sun, X., Wu, L. F., Altschuler, S. J. & Hata, A. N. Targeting therapy-persistent residual disease. Nat. Cancer 5, 1298\u20131304 (2024).","journal-title":"Nat. Cancer"},{"key":"66376_CR145","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.cell.2009.12.052","volume":"140","author":"EJ Park","year":"2010","unstructured":"Park, E. J. et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140, 197\u2013208 (2010).","journal-title":"Cell"},{"key":"66376_CR146","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1158\/2159-8290.CD-15-1177","volume":"6","author":"J Incio","year":"2016","unstructured":"Incio, J. et al. Obesity-induced inflammation and desmoplasia promote pancreatic cancer progression and resistance to chemotherapy. Cancer Discov. 6, 852\u2013869 (2016).","journal-title":"Cancer Discov."},{"key":"66376_CR147","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1016\/j.cell.2020.11.009","volume":"183","author":"AE Ringel","year":"2020","unstructured":"Ringel, A. E. et al. Obesity shapes metabolism in the tumor microenvironment to suppress anti-tumor immunity. Cell 183, 1848\u20131866 e1826 (2020).","journal-title":"Cell"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66376-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66376-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66376-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T16:03:54Z","timestamp":1763395434000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66376-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":147,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["66376"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-66376-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"12 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: S. Shen reports personal fees from Agence nationale de la recherche (France), Krebsliga Schweiz (Switzerland), KWF Kankerbestrijding (Netherlands), Austrian Research Funding, Belgian Foundation against Cancer, Shenzhen Medical Academy of Research and Translation (China), and serving as an Associate Editor for Oncogenesis (Springer Nature, London, UK); The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10048"}}